Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Rotavirus Prophylaxis Market, and What Factors Will Drive It?
In recent times, the market size for rotavirus prophylaxis has witnessed substantial growth. A rise from $9.05 billion in 2024 to $9.94 billion in 2025 is predicted, reflecting a Compound Annual Growth Rate (CAGR) of 9.8%. Factors such as vaccine availability and fairness, the emergence of new rotavirus strains, investment in research and development, and public health readiness have contributed to the growth during the historic period.
Expectations are high for a robust growth in the rotavirus prophylaxis market in the coming years. The market is projected to expand to$14.45 billion in 2029, with a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period can be linked to the global burden of gastrointestinal diseases, expansion efforts, immunization initiatives, and confidence in vaccines. The forecast period is likely to witness trends like next-generation vaccines, combination vaccines, innovative vaccine delivery systems, and global cooperation in immunization.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
What External and Internal Drivers Are Contributing to the Growth of theRotavirus Prophylaxis Market?
The growth of the rotavirus prophylaxis market is predicted to surge due to the rise in vaccine courses. A vaccine course, a designated dosage specifically conducted to offer protection against certain diseases, boosts the immune response, rendering remarkable protection against rotavirus infection. This enhanced immunity reduces the chances of battling diseases and augments the effectiveness of the vaccine. For example, UNICEF published a report in January 2022 revealing that approximately 5.71 million RV1-5 frozen rotavirus vaccine courses were produced with the expectation to hit 9.31 million by 2028. In addition, around 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were generated, which are forecasted to increase to 6.13 million by 2028. Consequently, the rise in vaccine production is set to stimulate the rotavirus prophylaxis market.
What Segment Types Define the Rotavirus Prophylaxis Market Structure?
The rotavirus prophylaxismarket covered in this report is segmented –
1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Rotarix: Single Dose; Multi-Dose
2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation
3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation
4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions
5) By Other Treatments: Supportive Care; Antidiarrheal Medications
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Rotavirus Prophylaxis Market?
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Rotavirus Prophylaxis Market?
Leading businesses in the rotavirus prophylaxis market are working on vaccine development in order to fulfill the needs of their customers. Obtaining vaccine approvals includes numerous development and testing phases, which are critical to ensure the safety and efficacy of these vaccines against this viral disease, especially in babies and young kids. An example of this was seen in November 2022 when GlaxoSmithKline PLC, a leading pharmaceutical and biotech firm in the UK, declared that the US Food and Drug Administration (FDA) had given the green light to an oral-dosing applicator-only format (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral), which wards off rotavirus gastroenteritis triggered by G1 and non-G1 types (G3, G4 and G9) in infants. The new oral-dosing applicator-only format is completely liquid and does not need to be reconstituted before application. Both ROTARIX lyophilized and liquid forms are given orally in a two-dose sequence, comprising of the same live, human-attenuated rotavirus strain and are produced using analogous methods.
View the full report here:
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
What Is the Definition of the Rotavirus Prophylaxis Market?
Rotavirus prophylaxis refers to the prevention of rotavirus infection through vaccination, which protects infants and young children from a highly infectious illness that causes stomach and bowel inflammation. The purpose is to protect from person from any severity.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13045
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model